Background Multiple prospective, randomized trials have demonstrated that the addition of adjuvant therapy after surgical resection of pancreatic cancer improves survival compared to surgery alone. However, the optimal type of adjuvant therapy, chemotherapy alone, or chemotherapy combined with chemoradiation therapy remains controversial. Our aim was to examine the treatment trends for surgically resectable (stages I and II) pancreatic cancer in the USA using the National Cancer Database. Methods The National Cancer Database (NCDB) is a national oncology outcomes database for over 1,500 Commission on Cancer accredited cancer programs. Patients diagnosed with stage I-II pancreatic adenocarcinoma between 2003 and 2010 were selected from the NCDB Hospital Comparison Benchmark Reports. Attention was paid to the initial treatment regimen, such as surgery alone, surgery plus chemotherapy, or surgery plus chemoradiation. In addition, data on hospital setting (teaching hospitals vs. community hospitals) were collected and analyzed. The Cochran-Armitage test for trend was used to assess changes in treatment over time.
The National Comprehensive Cancer Network continues to recommend adjuvant chemotherapy or chemotherapy combined with chemoradiation therapy for patients with resected pancreatic cancer. 8 We designed this study using the National Cancer Database (NCDB) to evaluate treatment trends for patients with resectable pancreatic cancer.
Methods
The National Cancer Database is a national oncology outcomes database for over 1,500 Commission on Cancer accredited cancer programs. The NCDB is a joint program of the American College of Surgeon's Commission on Cancer and the American Cancer Society. Institutional Review Board approval was received from our institution to access the database for this study; the database was accessed on February 15, 2013 .
Patients diagnosed with stage I and II pancreatic adenocarcinoma between 2003 and 2010 were selected from the NCDB Hospital Comparison Benchmark Reports. Data available for earlier years was not included because of a change to the American Joint Committee on Cancer staging system in 2003. Attention was paid to the initial treatment regimen, such as surgery alone, surgery plus chemotherapy, or surgery plus chemoradiation. The NCDB does not identify whether additional therapies were given in the adjuvant or neoadjuvant settings. Surgery plus radiation and chemotherapy is referred to interchangeably as "chemoradiation." We designated "nonsurgical therapy" to include chemotherapy only, chemoradiation only, or no first course treatment. The NCDB categorizes patients as receiving "other specified therapy" when the first course treatment does not fall under any of the abovementioned categories. We included these patients in our demographics and trend analysis, but excluded them from the analysis of predictive factors.
We defined private insurance as including managed care and any private insurance. Patients with government insurance included those with Medicaid, Medicare (with or without supplement), Veterans Affairs, Tricare/Military, or Indian/ Public Health Service. Patient comorbidities are recorded in the NCDB according to the Charlson Comorbidity Score using the Deyo method of mapping administrative codes. 9 We defined "non-white" ethnicity to include African-American, Hispanic, Asian/Pacific Islander, Native American, and other or unknown.
Data regarding hospital setting were collected and analyzed. The NCDB defined teaching hospitals as facilities associated with university medical schools or those designated as National Cancer Institute Comprehensive Cancer Care Programs. Teaching hospitals make up 18 % of the reporting hospitals and account for 33 % of cases in the NCDB. The NCDB defines community cancer centers as facilities that diagnose or treat 100-649 cancer cases annually, and comprehensive community cancer centers as facilities that treat 650 or more cancer cases annually. In this study, we considered community and comprehensive community cancer centers together and refer to them generally as "community hospitals." Community hospitals make up 74 % of all reporting hospitals and account for 63 % of cases in the NCDB. Hospitals that do not fulfill these criteria were categorized as "other" and make up the remaining portion of reporting hospitals in the NCDB.
We compared treatment trends over the 2003-2010 period with respect to type of treatment received, stage of pancreatic cancer, and hospital setting. The Cochran-Armitage test for trend was used to assess changes in treatment over time. We also compared demographics between the two hospital settings and assessed univariate factors influencing odds of a patient receiving surgery. Percent change is reported as change relative to 2003 treatment rates. Pearson's chi-squared test was used to compare categorical variables. The level of statistical significance was set to P <0.05. All reported P values are twotailed. Statistical analysis was done using JMP Pro 10.0 (Cary, NC) and GraphPad Prism 6 (La Jolla, CA).
Results

Demographics
A total of 59,094 patients with stage I and II pancreatic adenocarcinoma were included in the study. Table 1 shows patient demographics at community and teaching hospitals. With few exceptions, comparison between the two hospital settings for each patient demographic yielded a statistically significant difference. More patients in ≥80 age range were treated at community hospitals (24 %) compared to teaching hospitals (16.2 %); the proportion of patients in each age group was significantly different between hospital settings (P <0.05 for all). Community and teaching hospitals treated nearly equal portions of women (52.0 vs. 50.3 %; P <0.0001). Stage II disease was more commonly treated at teaching hospitals (76.3 vs. 69.1 %; P < 0.0001). The majority of patients had a Charlson comorbidity score of zero (68 %). Patients traveling over 50 miles were more likely to receive care at teaching hospitals than those traveling under 50 miles (odds ratio [OR] 3.18, 95% confidence intervals [CI] 3.042 to 3.313, P <0.0001).
Use of Surgery for Resectable Pancreatic Cancer
Since 2003, within each hospital setting, there has been no significant change in the rate at which patients with stage I or II pancreatic cancer receive surgery as a component of therapy. However, a comparison of hospital settings does reveal differences in the use of surgery as a component of therapy. Patients with stage I disease in 2010 received surgery at a rate of 31.8 % at community hospitals and 52.9 % at teaching hospitals (P < 0.0001) (Fig. 1a) . Patients with stage II disease in 2010 received surgery at a rate of 53.0 % at community hospitals and 60.3 % at teaching hospitals (P <0.0001) (Fig. 1b) .
Use of Surgery Alone
Use of surgery alone for treatment of stage I pancreatic adenocarcinoma did not change significantly at community or teaching hospitals from 2003 to 2010. In 2010, of stage I patients who underwent surgery, 66.4 and 64.6 % received surgery alone at community and teaching hospitals, respectively (P value not significant) (Fig. 2) . Use of surgery alone for stage II disease decreased significantly in both hospital settings over the observed period (P <0.0001 for both). Of stage II patients who underwent surgery at community hospitals in 2010, 33.6 % received surgery alone, representing an 11.0 % decrease from 2003 (Fig. 3a) . Similarly, of patients with stage II disease who underwent surgery at teaching hospitals in 2010, 38.7 % received surgery alone, a 20.8 % decrease from 2003 (Fig. 3b) . Stage II patients received surgery alone more frequently at teaching hospitals compared to community hospitals (P =0.0009).
Use of Radiation and Chemotherapy in Addition to Surgery
The use of surgery, radiation, and chemotherapy (SRC) decreased significantly across both stages at community and teaching hospitals (P <0.0001 for all). (Fig. 2b ). There was no significant difference in the rate of SRC for stage I disease at community hospitals compared to teaching hospitals. Of patients with stage II disease who underwent surgery at community hospitals, 39.3 % received SRC in 2010, a decrease of 25.8 % (Fig. 3a) . Of stage II patients who underwent surgery at teaching hospitals, 29.6 % received SRC in 2010, a 29.8 % decrease (Fig. 3b) . Stage II patients received SRC more frequently at community hospitals compared to teaching hospitals (P <0.0001).
Use of Chemotherapy in Addition to Surgery
Treatment with surgery plus chemotherapy increased significantly at both community and teaching hospitals for stage I and II disease (P <0.0001 for all). Of stage I patients who underwent surgery in 2010, 14.1 % received surgery and chemotherapy at community hospitals, an increase of 165.9 %. Likewise, 16.2 % received surgery and chemotherapy at teaching hospitals, an increase of 175.0 % (Fig. 2) . There was no significant difference in the use of surgery and chemotherapy for stage I disease at community hospitals compared to teaching hospitals. Of stage II patients who underwent surgery in 2010, 27.1 % received surgery and (Fig. 3a) . Similarly, 31.8 % received surgery and chemotherapy at teaching hospitals, a 250.4 % increase (Fig. 3b) . Stage II patients received surgery and chemotherapy more frequently at teaching hospitals compared to community hospitals (P =0.0014). (Fig. 4a) . However, a comparison of hospital settings does reveal differences in the use of nonsurgical therapy. Compared to 43.5 % at teaching hospitals (P <0.0001), 63.3 % of patients with stage I disease received nonsurgical therapy in 2010 at community hospitals. On the other hand, the use of nonsurgical therapy increased significantly at both community hospitals (P =0.0002) and teaching hospitals (P <0.0001) for stage II disease (Fig. 4b) . Compared to 35.8 % at teaching hospitals (P <0.0001), 43.4 % of community hospital patients with stage II disease received nonsurgical therapy in 2010.
Predictors of Surgery
Patients under 70 years of age were much more likely to receive surgery than those 70 or older, across both stages, and both hospital settings (P <0.0001 for all) ( Table 2 ). White patients with stage I disease treated at community hospitals were less likely to receive surgery than non-white patients (OR 0.88), but white patients with stage II disease were more likely to receive surgery (OR 1.2). White patients at teaching hospitals were more likely to receive surgery than non-white patients with stage I disease (OR 1.2) and stage II disease (OR 1.5).
Patients with a Charlson Comorbidity Score of two or higher were less likely to receive surgery than patients with a score of zero or one, across both stages, and at both hospital settings (p<0.05 for all). Patients with non-governmental insurance were more likely to receive surgery than patients with government insurance for stage I and II disease at both hospital settings (P <0.0001 for all). Patients at community hospitals were less likely to receive surgery than patients at teaching hospitals for both stage I and stage II disease (P < 0.0001 for both) (Fig. 4 ).
Discussion
The current study aimed to evaluate changes in the approach to treating resectable pancreatic cancer in the USA using a national oncology database. For both stage I and stage II disease, we found a significantly increased use of surgery plus chemotherapy and a concomitant decreased use of surgery plus chemoradiation therapy at both community and teaching hospitals. Furthermore, the rate of nonsurgical therapy remained alarmingly high, ranging from 36 to 63 % depending on hospital setting and disease stage.
Early randomized trials of adjuvant therapy for pancreatic cancer as well as institutional series studied the use of chemoradiation and found a survival benefit compared to surgery alone. 4 , 5 They too have shown a survival benefit compared to surgery alone. Taken as a whole, the results of all of these trials have clearly demonstrated a benefit to adjuvant therapy after the resection of pancreatic cancer. However, there is no consensus as to the optimal type of adjuvant therapy. In the USA, the National Comprehensive Cancer Network recommends either chemotherapy or chemotherapy combined with chemoradiation therapy, 8 whereas in Europe, the European Society for Medical Oncology recommends adjuvant chemotherapy. 12 In either case, novel therapies are desperately needed to further improve survival after the resection of pancreatic cancer. 13 The data in our study reveal a change in the approach to adjuvant therapy for pancreatic cancer in the USA. From 2003 to 2010, the use of chemotherapy alone increased up to 250 % depending on the disease stage and hospital setting. During the same time, the use of chemoradiation decreased up to 42 % depending on the disease stage and hospital setting. These findings parallel to some degree the time course of publication of the previously referenced clinical trials. That is to say, with the more recent publication of the trials emphasizing chemotherapy alone, the use of chemotherapy alone started to increase. Despite this increase in the use of chemotherapy alone, in 2010, there remained a slightly greater use of chemoradiation as adjuvant therapy for pancreatic cancer.
The current study does reveal some concerning issues regarding the management of resectable pancreatic cancer. Despite all the evidence showing a benefit to the use of adjuvant therapy for pancreatic cancer, our data show that of those patients who underwent resection of pancreatic cancer in 2010, one third to two thirds did not receive adjuvant therapy. This lack of delivery of adjuvant therapy, while concerning, is not too surprising. Single institution studies have shown that as few as 47 to 74 % of patients receive adjuvant therapy after resection of pancreatic cancer.
14 , 15 However, one series demonstrated that 91 % of patients who had a periampullary cancer resected received adjuvant therapy. 16 There are a number of reasons why the rate of delivery of adjuvant therapy is so low. They include prolonged postoperative recovery, interval discovery of metastatic disease, social circumstances, and patient refusal. 17 While the suboptimal delivery of adjuvant therapy for pancreatic cancer is a concern, a more pressing issue is the continued national failure to utilize surgery in the management of patients with resectable pancreatic cancer. Using the National Cancer Database, Sener et al. cancer resected. 19 Our analysis of the National Cancer Database from 2003 to 2010 showed that only 43.4 % of patients with stage I disease and only 59.7 % of patients with stage II disease had their pancreatic cancer resected. Though there has clearly been an increased utilization of surgery for resectable pancreatic cancer over the last three decades, there remains a significant portion of patients who do not receive the treatment that has the most important impact on the chances for long-term survival and a potential cure.
With regard to patients who did not receive surgery for early stage pancreatic cancer, Bilimoria et al. found that while the rate of pancreatectomy increased and the percentage of patients not receiving treatment decreased between 1995 and 2004, 38.2 % of patients were not offered surgery and another 13.5 % had no documented reason for not receiving surgery. 20 We found a surprisingly high rate of nonsurgical therapy being utilized for treatment of resectable pancreatic cancer. Sixtythree percent of patients with stage I disease at community hospitals and 43.5 % at teaching hospitals did not receive surgery in 2010. These rates did not change significantly from 2003. Similarly, 43.4 % of patients with stage II disease at community hospitals and 35.8 % at teaching hospitals did not receive any surgery as part of their first course treatment. These rates, however, increased significantly from 2003.
Bilimoria et al. found that several factors were associated with patients not receiving surgery including older age, black race, lower annual income, less education, and Medicare or Medicaid insurance. 20 The report also found that patients were less likely to receive surgery at community hospitals. Here, we report parallel findings of factors associated with a decreased likelihood of receiving surgery. Our univariate analysis demonstrated that patients were less likely to undergo surgery if they were 70 years of age or older, of non-white race, had a Charlson Comorbidity Score of 2 or higher, had government insurance, or were treated at community hospitals. These findings from the 2003-2010 period paired with those of Bilimoria et al. from 1995 Bilimoria et al. from -2004 indicate that little has changed in patient access to pancreatic surgery in the past two decades. While the use of adjuvant treatment improves, limitations remain in the basic ability to provide patients with surgical therapy for resectable pancreatic cancer. Interestingly, recently presented research by Lee et al. showed that race does not impact treatment and survival in an equal access federal health care system. 21 Several factors may contribute to the substandard delivery of surgical therapy for resectable pancreatic cancer. Elderly patients often chose to forgo invasive surgery. In 2010, 20.1 % (n =259) of patients with stage I disease and 15.5 % (n =622) of patients with stage II disease at teaching hospitals were age Riall and Lillemoe noted two additional possibilities for the lack of surgery in qualified patients: (1) lack of referral to a surgeon for evaluation because of nihilistic views regarding pancreatic cancer among primary physicians, gastroenterologists, and oncologists and (2) surgical evaluation by a surgeon who was not experienced in performing pancreatic resection. 22 Several studies have documented lower rates of morbidity and mortality as well as increased survival when patients undergo pancreatic resection at high-volume centers.
23 -25 The centralization of treatment for patients requiring complex pancreatic surgery will continue to be a major determinant in patient outcomes, and efforts need to be increased in order to meet the standard of care for early stage pancreatic cancer. Furthermore, more progress needs to be made in rapid referral of patients with early stage pancreatic cancer to experienced pancreatic surgeons. It is likely that the systems for an efficient referral system are lacking since research has shown that both primary care and specialist physicians are enthusiastic about using electronic referral systems. 26 , 27 Our study has several potential limitations. First, the data available in the NCDB were only accessible in aggregate form and not as individual patient information. As a result, we were limited to only univariate analysis of variables. Second, the patient demographics between community hospitals and teaching hospitals were widely different in some categories, including age and distance traveled for care. These demographic variations may underscore the different rates of treatment utilization between community and teaching hospitals. Third, the NCDB does not identify between adjuvant or neoadjuvant chemotherapy and/or radiation that patients receive. As a result, there may be skewing of the treatment trends since this study intends to study the utilization of adjuvant therapies only.
Conclusion
The treatment of resectable pancreatic cancer is changing in the USA. An increasing proportion of patients are receiving chemotherapy in addition to surgery with a concomitant decline in the utilization of adjuvant chemoradiation therapy. There remains an unacceptably large percentage of patients with resectable pancreatic cancer who do not receive surgery as a component of their therapy.
